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Abstract 
Background: Impactful greenhouse gas emissions abatement can now be achieved through gas fermentation using 
acetogenic microbes for the production of low-carbon fuels and chemicals. However, compared to traditional hosts 
like Escherichia coli or yeast, only basic genetic tools exist for gas-fermenting acetogens. To advance the process, a 
robust genetic engineering platform for acetogens is essential.
Results: In this study, we report scarless genome editing of an industrially used model acetogen, Clostridium 
autoethanogenum, using the CRISPR/Cas9 system. Initial efforts to retrofit the CRISPR/Cas9 system for C. autoethano-
genum resulted in poor efficiency likely due to uncontrolled expression of Cas9. To address this, we constructed and 
screened a small library of tetracycline-inducible promoters that can also be used to fine-tune gene expression. With 
a new inducible promoter, the efficiency of CRISPR/Cas9-mediated desired gene deletion in C. autoethanogenum was 
improved to over 50 %, making it a viable tool for engineering C. autoethanogenum.
Conclusions: Addition of both an inducible promoter library and a scarless genome editing tool is an important 
expansion to the genetic tool box of industrial C. autoethanogenum strain.
Keywords: Acetogen, CRISPR/Cas9, Gas fermentation, Clostridium autoethanogenum, Genome editing, Inducible 
promoter
© 2016 The Author(s). This article is distributed under the terms of the Creative Commons Attribution 4.0 International License 
(http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, 
provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, 
and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/
publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Background
Global greenhouse gas emissions have been rising at an 
unprecedented rate, with the associated climate insta-
bility now being recognized throughout the world by 
governments as a serious threat to ecosystems, human 
health, and national economies. To curtail this trend 
and limit the global temperature rise to 2  °C above pre-
industrial levels will require a radical reduction of the 
use of primary fossil resources for the coming decades 
[1] and increase the use of low-carbon fuels and chemi-
cals [2] derived from sustainable and waste sources. Gas 
fermentation offers an opportunity to recycle carbon 
and harness energy from synthesis gas (syngas) gener-
ated from any biomass (such as municipal solid waste, 
organic industrial waste, or agricultural waste) or indus-
trial off-gases (e.g., from industrial sources like steel mills 
or processing plants) for the production of transportation 
fuels and chemical intermediates [3, 4]. The commerciali-
zation and at-scale deployment of gas fermentation tech-
nology is being actively pursued by several companies 
with the first commercial units currently under construc-
tion [4, 5]. At the heart of the technology are acetogenic 
bacteria that act as biocatalysts by fixing carbon from 
gases such as carbon monoxide and/or carbon dioxide in 
the presence of hydrogen [6]. The principle challenges in 
commercial exploitation of the vast potential of gas-fer-
menting acetogens are the relatively basic understanding 
of acetogens and, in particular, the limited availability of 
genetic tools and high-throughput genetic engineering 
platforms [2, 7].
Clostridium autoethanogenum is a model acetogen 
that is being pursued for fuel (ethanol) and chemical 
(2,3-butanediol) production at commercial scale [4, 5]. 
However, relatively few genetic tools have been reported 
for C. autoethanogenum [4, 5]. In C. autoethanogenum, 
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key insights on the energetics and carbon flux balance 
have been gained by gene knockout studies using Clos-
Tron, a group II intron-based retrohoming gene disrup-
tion tool [8, 9]. However, this intron insertion-based gene 
inactivation tool has its own limitations as it leaves a 
huge scar consisting of a fragment of the group II intron 
along with the antibiotic selection marker. Gene dele-
tions by homologous recombination in C. autoethano-
genum [10] are achievable but at a very low frequency 
leading to labor-intensive screening processes and lower 
efficiencies or by leaving a scar or marker in the genome. 
A more reliable and stable genetic modification tool that 
enables scarless genome modifications is preferable.
CRISPR/Cas9 system is an exciting breakthrough in 
DNA editing technology. Clustered Regularly Inter-
spaced Short Palindromic Repeat, CRISPR, is a bacte-
rial acquired immune system to combat phage infections 
that has been intelligently adapted for biotechnology 
purposes [11–13]. CRISPR/Cas9 from Streptococcus pyo-
genes relies on a 20-nucleotide information in its crRNA–
tracrRNA chimeric RNA (single-guide RNA, sgRNA) 
to guide Cas9 endonuclease to the target DNA where it 
introduces double-stranded breaks (DSB). In most eukar-
yotes, the DSB are repaired by non-homologous end 
joining. However, in prokaryotes the repair is by homolo-
gous recombination and is mediated by a DNA repair 
template. CRISPR/Cas9-mediated genome modification 
has been shown in a diverse array of microbial systems 
including in a few Clostridia, recently [14–18].
Here we describe the applicability of Streptococcus 
pyogenes type II CRISPR/Cas9 system for genetic modi-
fication of C. autoethanogenum which already has a 
type-1B CRISPR [19]. We further show that the adapta-
tion of the heterologous CRISPR/Cas9 system for use in 
C. autoethanogenum required constructing and screen-
ing a small library for stronger tetracycline-inducible 
promoter(s). For the exemplification of the CRISPR/
Cas9 system, two genes, namely a NADPH-dependent 
primary:secondary alcohol dehydrogenase (adh; CAE-
THG_0553) and a 2,3-butanediol dehydrogenase (2,3-
bdh; CAETHG_0385), were chosen. The rationale for 
targeting these genes is centered on their involvement 
in ethanol and 2,3-butanediol metabolism [20, 21] and 
the fact that both genes had been previously inactivated 
(using ClosTron methodology) without having an impact 
on growth [10, 22], thus making them predictable targets 
for genetic tool validation.
Results and discussion
The cas9 and sgRNA derived from S. pyogenes CRISPR/
Cas9 system were introduced into C. autoethanogenum 
on two different plasmids, sequentially. Except for in 
controls, the sgRNA plasmids contained the homology 
arms (HAs) that served as DNA editing template. While 
C. autoethanogenum maintained sgRNA plasmids, sev-
eral attempts to introduce a plasmid carrying cas9 under 
the control of a native constitutive phosphotransacety-
lase–acetate kinase promoter [20] were not successful, 
likely due to toxicity caused by uncontrolled Cas9 protein 
expression. This was addressed by regulating the expres-
sion of cas9 by a tetracycline-inducible promoter, tet3no 
[23]. Two sgRNAs with unique binding sites to the tar-
get gene (Fig. 1a, b) were individually expressed using a 
native Wood–Ljungdahl cluster promoter [24].
The adh gene was targeted first (Fig. 1a). Following con-
firmation of the presence of cas9 by PCR (Fig.  1a, con-
trol-1), sgRNA plasmids with (psgRNA-adh-T1_HA and 
psgRNA-adh-T2_HA) and without HA (psgRNA-adh-T1) 
were then introduced. The cas9 expression in colonies 
transformed with cas9 and sgRNA plasmids was induced 
with 32  ng/ml anhydrotetracycline. The induced colonies 
were then screened for 891 bp deletion within adh by PCR 
using primers flanking the HA (Fig. 1a). In the absence of 
HA or DNA editing template, no deletion was detected 
(Fig.  1a, Control-2) and Sanger sequencing of these PCR 
products did not show insertions/deletions (INDELs). 
Four colonies were obtained on screening plates with 
psgRNA-adh-T1_HA and psgRNA-adh-T2_HA. Inter-
estingly, amplicons of ~2.9 kbp instead of a ~2.5 kbp size 
were detected in two colonies with psgRNA-adh-T1_HA 
(Fig.  1a, T1, 1 and 2), implying a partial deletion in adh 
rather than the expected  ~0.9-kbp deletion. From the 
remaining two colonies (Fig. 1a, T1, 3 and 4), no fragment 
was amplified implying a probable integration of the plas-
mid at the target locus. Sanger sequencing of ~2.5 kbp PCR 
amplicons confirmed the partial deletion in adh (Fig.  1a, 
∆adh clone T1.1 and 1.2; Additional files 1, 2). The mutants 
with anticipated length of deletion were not generated. 
Two of the four colonies from psgRNA-adh-T2_HA ampli-
fied fragments corresponding to the wild type (Fig. 1a, T2, 
3 and 4), and the remaining two, similar to psgRNA-adh-
T1_HA, likely have the plasmid integrated at the targeted 
locus (Fig. 1a, T2, 1 and 2). This could be likely due to poor 
recognition of the target site by guide RNA adh-T2.
The partial deletion of adh only in the presence of all 
three components: cas9, sgRNA, and DNA editing tem-
plate indicated the activity of the heterologous CRISPR/
Cas9 system in C. autoethanogenum and scope for fur-
ther improvement. To further optimize the CRISPR/Cas9 
system for improved performance in C. autoethanoge-
num, two modifications were identified: (1) enhanced 
control of cas9 expression and (2) positioning one of the 
HAs close to Cas9 cleavage site.
In order to have an enhanced control over cas9 expres-
sion, a set of variants of tetracycline-inducible promoters 
was constructed based on a method described previously 
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[25] whereby the ten least conserved bases in the −35 
and −10 boxes of the rRNA consensus sequences of 
C. autoethanogenum were randomized. For inducible 
expression, the tet operator (tet3no) from the tetracy-
cline-inducible promoter system [26] was inserted in 
between the randomized −35 and −10 boxes (Fig.  2a). 
Twelve variants from the inducible promoter library 
(IPL) were screened with chloramphenicol acetyltrans-
ferase gene catP as the reporter. Five of these variants 
could not be grown in liquid media, possibly due to the 
strength of these promoters. Of the seven remaining pro-
moters, (IPL1 2, 3, 5, 8, 11, and 12), only IPL12 promoter 
showed significant activity. Even though the non-induced 
IPL12 promoter showed leaky activity that was higher 
than the original tet3no promoter, upon induction the 
activity of IPL12 promoter was  approximately  ninefold 
higher than that of tet3no (Fig. 2b). Therefore, the IPL12 
promoter was chosen to drive cas9 expression (Fig. 1b).
The modifications discussed above were tested on a 
second gene, 2,3-bdh. The expression of cas9 was driven 
by IPL12 promoter (IPL12-cas9) and at least one of the 
HAs was designed to be within 80 bp from Cas9 cleavage 
site (Fig. 1b) unlike in the previous case where it was at a 
distance of 250 bp (Fig. 1a) as a measure to avoid poten-
tial partial deletion.
Following cas9 induction, colonies harboring pIPL12-
cas9 and one of the two sgRNA plasmids, psgRNA-
2,3bdh-T1_HA and psgRNA-2,3bdh-T2_HA, were 
screened by PCR for deletion in 2,3-bdh using prim-
ers flanking the HAs. While a  ~3.5-kbp fragment was 
amplified from wild type and colonies carrying either 
pIPL12-cas9 or psgRNA-2,3bdh-T1_HA or psgRNA-
2,3bdh-T2_HA only (Fig. 1b, control, lanes w, 1, 2, and 
3), a deletion product of ~2.5 kbp was observed in colo-
nies (Fig.  1b, T1 lanes 2-6 and T2 lanes 1-3, 5, and 8) 
carrying cas9, sgRNA, and DNA editing template. The 
desired modification was observed with both sgRNAs 
targeting 2,3-bdh. This  ~1-kbp deletion within 2,3-bdh 
was further confirmed by sequencing the PCR prod-
ucts from sgRNA T1, clone 2 (Fig.  1b, ∆2,3-bdh clone 
T1.2; Additional file 3), and sgRNA T2 clone 1 (Fig. 1b, 
∆2,3-bdh clone T2.1; Additional files 1, 4). The plasmids 
from positive clones were cured while maintaining the 
gene deletion by passaging the strains twice on non-
selective agar plates. With five out of six and four out 
of eight colonies harboring cas9, DNA editing template, 
and either sgRNA T1 or T2 having desired deletion 
in 2,3-bdh, the efficiency of the re-designed system to 
introduce desired deletion was >50 % compared to the 
previous attempt.
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Fig. 1 CRISPR/Cas9-based editing of C. autoethanogenum. a, b show design and screening for editing adh and 2,3-bdh, respectively. The modifica-
tions in the design for editing 2,3-bdh such as the position of the homology arms (5′HA and 3′HA, checkered gray box) relative to Cas9 cleavage site 
(T1 and T2; scissors) and cas9-inducible expression from IPL12 are highlighted in red. The alignment of sequence from Sanger sequencing of three 
clones (a ∆adh clone T1.1, ∆adh clone T1.2 and b ∆2,3-bdh clone T2.1) and next-generation sequencing (MiSeq; B, ∆2,3-bdh clone T1.2) confirms the 
partial deletion in adh and expected deletion in 2,3-bdh
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Conclusions
In conclusion, the data reported herein demonstrate the 
workability of the CRISPR/Cas9 tool in C. autoethanoge-
num. In order to efficiently work in C. autoethanogenum, 
the CRISPR/Cas9 system requires the controlled expres-
sion of cas9 and the constitutive expression of sgRNA in 
the presence of DNA editing template. The new IPL12 
tetracycline-inducible promoter significantly increased 
the efficiency of Cas9-mediated genome editing. Even 
with screening a relatively small library, promoters with 
a wide range of expression strengths ranging between 
the original tet3no to the strong IPL12 promoter were 
obtained. The developed promoter library has the added 
potential of expanding the prospective applications of 
this approach in the metabolic engineering of acetogens. 
With our modifications, we achieved  >50  % efficiency 
in gene deletion, which is comparable to the efficiencies 
reported in other Clostridia. The efficiency of CRISPR/
Cas9 system adapted for Clostridium beijerinckii is 
unclear [15, 27]. However, Li et al. reported editing effi-
ciencies of up to 100 % in C. beijerinckii and Clostridium 
acetobutylicum with the use of nickase variant of cas9 
[18]. In Clostridium cellulolyticum, gene deletions were 
only possible with an engineered nickase variant of cas9 
as the wild-type cas9 could not be introduced in C. cel-
lulolyticum [14]. The use of an inducible promoter to 
control the expression of wild-type cas9 would have 
probably been sufficient to overcome the problem of 
expressing wild-type cas9 in C. cellulolyticum. Likewise, 
combining an engineered nickase with the inducible pro-
moter may add additional benefit. In Clostridium ljun-
gdahlii, gene deletions with 50–100  % efficiency have 
been reported with a single-plasmid system comprising 
both cas9 and guide RNA expression cassettes with Pthl 
and ParaE constitutive promoters driving the expression 
of cas9 and guide RNA, respectively [17]. The expression 
of cas9 from a constitutive promoter could have been 
likely possible due to the absence of a CRISPR system in 
C. ljungdahlii [19]. The expression of guide RNA from 
C. acetobutylicum’s ParaE promoter, similar to that in 
C. ljungdahlii, and the use of nickase-only Cas9 variant 
may further improve the efficiency of the CRISPR/Cas9-
based genome editing in C. autoethanogenum. The above 
CRISPR/Cas9-based genome editing strategy can be fur-
ther adapted for gene insertions and to create multiple 
gene knockouts [11, 12].
Methods
Strain and cultivation
A derivative strain of C. autoethanogenum type strain 
DSM10061 [28] was obtained from Deutsche Sammlung 
von Mikroorganismen und Zellkulturen (DSMZ), Ger-
many, and grown under strict anaerobic condition as 
described earlier [21].
Construction of CRISPR/Cas9 plasmids
The Type II CRISPR/Cas9 system from Streptococ-
cus pyogenes was used in this study [13]. The cas9 gene 
was codon adapted to C. autoethanogenum using Gen-
Script’s algorithm and C. autoethanogenum codon fre-
quency table. The codon-adapted cas9 gene (GenBank: 
KU867916) was synthesized by GenScript. The gene 
was cloned into vectors pLZtet3no [23] and pIPL12 
(described below) between NdeI and NheI restriction 
endonuclease sites. The resulting vectors are referred as 
ptet3no-cas9 and pIPL12-cas9. The expression of cas9 
is under the control of an anhydrotetracycline-inducible 
promoter, tet3no [23] in ptet3no-cas9, and a variant of 
tet3no promoter in pIPL12-cas9 (discussed below).
Two genes, adh and 2,3-bdh, were targeted by CRISPR/
Cas9 system. Two sgRNAs, adh-T1 (5′-TAATTGGT 
ATAGGAGCTGT-3′) and adh-T2 (5′-CAATCGCATC 
ATAAGGACC-3′) for adh and 2,3bdh-T1 (5′-GAAGG 
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Fig. 2 Design and screening of tetracycline-inducible promoter 
variants with catP as a reporter. Shown in a are the sequences of the 
original Tet3n0 promoter and seven synthetic inducible promoters. 
The randomized non-conserved bases in −35 and −10 promoter 
elements are highlighted in red. Shown in b is the activity of catP 
reporter under tet3no and inducible promoters 1–12. The catP activ-
ity is expressed in Units/g protein. The inset shows the catP activity of 
weak promoters on a smaller scale
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ATGGTGTGGTATATG-3′) for 2,3-bdh, were designed 
and synthesized by GenCRISPR, GenScript’s CRISPR 
services platform. The specificity of all sgRNAs was 
tested against C. autoethanogenum genome sequence 
(GenBank accession number CP006763) [19] and two 
with unique binding site to the target gene preferably 
to the start and center of genes (Fig. 2a, b) were chosen 
for further study. The sgRNA was introduced into plas-
mid pMTL83157 [24] between NdeI and NheI. The  ~1 
kbp 5′ and 3′ homology arms (HAs) of adh (CP006763; 
position 609,136–610,050 and 610,518–611,451, respec-
tively) and 2,3-bdh (CP006763; position 412,243–412,231 
and 414,199–415,144, respectively) were PCR amplified 
from C. autoethanogenum using oligonucleotides listed 
in Table 2. The HAs were cloned into sgRNA plasmids at 
FseI restriction site for adh and PmeI restriction site for 
2,3-bdh. The resulting vectors are referred as psgRNA-
adh-T1_HA, psgRNA-adh-T2_HA, psgRNA-2,3bdh-T1_
HA, and psgRNA-2,3bdh-T2_HA, respectively.
Construction of variants of inducible promoter
To construct a variant set of inducible promoters, a 
long oligonucleotide was synthesized by Integrated 
DNA Technologies (IDT) containing the randomized 
sequences between the −35 and the −10 boxes in the 
rRNA consensus sequences (Fig.  1a), a ribosomal bind-
ing site (RBS), and the start codon of the chlorampheni-
col acetyltransferase (catP) gene (GenBank EF525477.1). 
This was annealed at its 3′ end to the start codon of the 
catP gene, and using a reverse oligonucleotide Og17 
(annealing to the 3′ end of the catP), a large (~864  bp) 
fragment incorporating these elements was amplified. 
This fragment was cloned using ClaI and NheI into the 
pLZtet3no [23] plasmid. The catP gene cloned down-
stream of tet3no-inducible promoter between NdeI and 
NheI restriction sites in pLZtet3no [23, 29] was used as a 
reference.
Strain construction
All vectors were introduced into C. autoethanogenum 
via conjugation as described previously [9]. Strains of C. 
autoethanogenum carrying ptet3no-cas9, pIPL12-cas9, 
psgRNA-2,3bdh-T1_HA, or psgRNA-2,3bdh-T2_HA 
were first constructed. Following the growth of colonies 
carrying these plasmids on agar plates containing 5  µg/
ml clarithromycin or 7.5 µg/ml thiamphenicol and 10 µg/
ml trimethoprim (to counter-select E. coli conjugation 
donor strain), they were screened to confirm the presence 
of cas9 by PCR using oligonucleotides Og05 and Og06 
(Fig.  1a, control-1). A C. autoethanogenum strain bear-
ing the tet3no-cas9 was re-transformed with plasmids 
psgRNA-adh-T1_HA or psgRNA-adh-T2_HA. Similarly, 
a C. autoethanogenum strain carrying pIPL12-cas9 was 
re-transformed with plasmids psgRNA-2,3bdh-T1_HA 
or sgRNA-2,3bdh-T2_HA. Following outgrowth on selec-
tive agar plates consisting of 7.5 µg/ml thiamphenicol (to 
propagate sgRNA plasmids), 5 µg/ml clarithromycin, and 
10 µg/ml trimethoprim, colonies were streaked on plates 
also containing 32  ng/ml anhydrotetracycline (Sigma; 
37,919) to induce the expression of cas9. The resulting 
colonies were screened for modification in adh or 2,3-
bdh locus using oligonucleotides Og13/Og14 and Og15/
Og16, respectively. Using a similar protocol, transconju-
gants carrying ptet3no-cas9 and sgRNA-adh-T1 without 
HA were constructed. The adh locus in transconjugants 
carrying ptet3no-cas9 and sgRNA-adh-T1 without HAs 
or DNA editing template was screened using primers 
Og09/Og10 (Fig.  1a, control-2). All conjugation experi-
ments with plasmids carrying sgRNA and HA were per-
formed in at least duplicate.
The lists of all plasmids and oligonucleotides with 
sequences used in this work are listed in Tables 1 and 2, 
respectively.
Chloramphenicol acetyltransferase (CAT) assay
Clostridium autoethanogenum strains containing plas-
mids with the synthetic inducible promoter variants were 
grown on PETC-MES media supplemented with clarithro-
mycin (5 µg/ml) until the cell density reached OD600 of 1. 
The cells were then sub-cultured to an OD600 of 0.1, and 
grown until an OD600 of 0.5 was reached. At this stage, the 
culture was split into 2 volumes, with one being induced 
with 31.6  ng/µl of anhydrotetracycline and the other left 
non-induced. The cultures were grown under these condi-
tions for 6 h, and 2 ml of culture was pelleted and resus-
pended in 1 ml phosphate buffered saline buffer. Cells were 
sonicated at 20 mA, for 30 s on and 30 s off for 6 cycles. 
Following sonication, the debris was pelleted, and the 
supernatant was used for CAT assays as described earlier 
[30].
Sanger sequencing and data analysis
The cleaned PCR products were Sanger sequenced by 
QuintaraBio (http://www.quintarabio.com/services). 
The resulting ABI chromatograms were processed with 
Geneious version  9.0.5 software (http://www.geneious.
com, [31]) that automatically calls bases with consen-
sus threshold at 85 %. The sequences were then aligned 
to reference which was either adh (CP006763; 608,975–
611,467) or 2,3-bdh (CP006763; 411,994–415,316) locus.
MiSeq and data analysis
The cleaned PCR product of ∆2,3-bdh clone T1.2 was 
subjected to MiSeq sequencing in-house. The Nextera 
DNA Library Preparation Kit from Illumina was used 
to prepare the library as per the protocol recommended 
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Table 1 List of plasmids used in this study
The table also includes the main features of plasmids
Plasmid Features References
pLZtet3no Original tet3no promoter derived from Clostridium base vector pMTL82251 with pBP1 replicon, ermB marker and 
catP as a reporter gene
[23]
pTet3no-cas9 Cas9 between NdeI and NheI sites in pLZtet3no This study
pIPL1 Tet3no promoter in pLZtet3no is replaced with IPL1 promoter This study
pIPL2 Tet3no promoter in pLZtet3no is replaced with IPL2 promoter This study
pIPL3 Tet3no promoter in pLZtet3no is replaced with IPL3 promoter This study
pIPL5 Tet3no promoter in pLZtet3no is replaced with IPL5 promoter This study
pIPL8 Tet3no promoter in pLZtet3no is replaced with IPL8 promoter This study
pIPL11 Tet3no promoter in pLZtet3no is replaced with IPL11 promoter This study
pIPL12 Tet3no promoter in pLZtet3no is replaced with IPL12 promoter This study
pIPL12-cas9 Cas9 between NdeI and NheI sites in pIPL12 This study
pMTL83157 pMTL83151 vector PWL promoter from C. autoethanogenum [24]
pgRNA-adh-T1 pMTL83157 with gRNA T1 targeting adh gene This study
pgRNA-adh-T2 pMTL83157 with gRNA T2 targeting adh gene This study
pgRNA-2,3bdh-T1 pMTL83157 with gRNA T1 targeting 2,3bdh gene This study
pgRNA-2,3bdh-T2 pMTL83157 with gRNA T2 targeting 2,3bdh gene This study
pgRNA-adh-T1_HA pMTL83157 with gRNA T1 targeting adh gene with homology arms This study
pgRNA-adh-T2_HA pMTL83157 with gRNA T2 targeting adh gene with homology arms This study
pgRNA-2,3bdh-T1_HA pMTL83157 with gRNA T1 targeting 2,3bdh gene with homology arms This study
pgRNA-2,3bdh-T2_HA pMTL83157 with gRNA T2 targeting 2,3bdh gene with homology arms This study
Table 2 List of oligonucleotides used in this study
The table also includes the purpose of each oligonucleotide
Oligonucleotide Sequence (5′ → 3′) Purpose
Og01 GATTATAAGCGGCCGGCCATAAACTATTTTTTAAAGATAAAAGCT PCR amplification of 5′-HA of adh
Og02 TACGCCGCCAGGTTTAACCAAAACCAGCTTGGACTTCTAAAGA PCR amplification of 5′-HA of adh
Og03 TCTTTAGAAGTCCAAGCTGGTTTTGGTTAAACCTGGCGGCGTA PCR amplification of 3′-HA of adh
Og04 CAACTTGCCCACTGGCCGGCCTGACTATTTCACTATGAGTAAATGGT PCR amplification of 3′-HA of adh
Og05 GAATGTGTTTAAACTCTCTGAAACTAGCAAATTTGG PCR amplification of 5′-HA of 2,3bdh
Og06 GAGATAATTATGAAAGCTGTATTGTGGTTGTAAAAGAAGGATTTGAAACAC PCR amplification of 5′-HA of 2,3bdh
Og07 GTGTTTCAAATCCTTCTTTTACAACCACAATACAGCTTTCATAATTATCTC PCR amplification of 3′-HA of 2,3bdh
Og08 AAAGGAGTTTAAACGAAAGTGAGCTTTTTGGTTATGAAAA PCR amplification of 3′-HA of 2,3bdh
Og09 TATTAACCTTATAAAGTCCTACCCC For screening
Og10 TAATCCTCCTCTTATAGTTTTGTGA For screening
Og11 CAAAAGCTATACTTAGTGCTAGATT For screening
Og12 TCATTTCTCTATCTTCAAAAAGTGT For screening
Og13 AGCTGTAGATAACAATGGGATCAT For screening
Og14 GTGAGATATAATGAGAAACCTGATCC For screening
Og15 AATGGCAGGGCAGATAATTGTAATG For screening
Og16 AAGGCATTCTGAGCCAGTTCTTTTA For screening
Og17 TAACGTCCTTAACTATTTATCAATTCGATCGACTAT To construct variants of ptet3no
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by the supplier. The library was sequenced on MiSeq 
instrument to get 2× coverage with reads of 150 bp. The 
2 × 2879 reads were paired and the resulting paired reads 
assembly was mapped to the reference 2,3-bdh locus 
(CP006763; 411,994–415,316) using built-in Read Map-
per in Geneious version 9.0.5 software. The consensus 
sequence was generated using highest quality threshold 
that uses chromatogram quality to call the best base.
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